Zosano Pharma, Inc. to Present Positive Phase 2 Results of Its Transdermal Patch for Osteoporosis  
3/31/2009 10:56:32 AM

FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of ZP-PTH, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established osteoporosis will be presented as a poster at the 8th International Symposium on Osteoporosis in Washington D.C.